$VRTX · Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated filed a Form 4 with the SEC on October 22, 2026, reporting a change in beneficial ownership by Daniel J. Brennan, a director of the company. The filing discloses that on October 20, 2026, Brennan acquired 795 shares of Vertex common stock at a price of $503.47 per share.
The shares were received as a restricted stock unit award. According to the filing, the award vests on the first anniversary of the grant date, subject to certain limited exceptions. Following the transaction, Brennan directly held 795 shares of Vertex common stock.
The Form 4 does not report any sales or other dispositions of securities by Brennan. The filing was signed by an attorney-in-fact on his behalf.